Following the FDA approval of Keytruda (pembrolizumab) for the treatment of first-line non-small cell lung cancer Oct. 24, Merck & Co. Inc. is poised to establish a lead and potentially dominate long-term in what is expected to be one of the largest commercial markets for immuno-oncology treatments.
Getting patients tested for the PD-L1 biomarker has been a challenge for Keytruda in second-line NSCLC, but physicians are already picking up the pace of testing in the last few...